Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

✍ Scribed by Ou, S.- H. I.; Janne, P. A.; Bartlett, C. H.; Tang, Y.; Kim, D.- W.; Otterson, G. A.; Crino, L.; Selaru, P.; Cohen, D. P.; Clark, J. W.; Riely, G. J.

• Book ID: 121491791
• Publisher: Oxford University Press
• Year: 2014
• Tongue: English
• Weight: 160 KB
• Volume: 25
• Category: Article
• ISSN: 0923-7534
• DOI: 10.1093/annonc/mdt572